HRP20000494B1 - Pharmaceutically active morpholinol - Google Patents

Pharmaceutically active morpholinol

Info

Publication number: HRP20000494B1
Authority: HR; Croatia
Prior art keywords: pharmaceutically active; morpholinol; pharmaceutically acceptable; active morpholinol; solvates
Prior art date: 1998-01-21

Application number

HR20000494A

Other languages

English (en)

Croatian (hr)

Inventor

Frederick Morgan Phillip

Lee Musso David

Joseph Partridge John

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-20

Publication date

2009-02-28

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

1999-01-20 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2000-12-31 Publication of HRP20000494A2 publication Critical patent/HRP20000494A2/hr

2009-02-28 Publication of HRP20000494B1 publication Critical patent/HRP20000494B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR20000494A 1998-01-21 1999-01-20 Pharmaceutically active morpholinol HRP20000494B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (2)

Publication Number	Publication Date
HRP20000494A2 HRP20000494A2 (en)	2000-12-31
HRP20000494B1 true HRP20000494B1 (en)	2009-02-28

Family

ID=26312986

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HR20051024A HRP20051024A2 (hr)	1998-01-21	1999-01-20	Farmaceutski aktivni morfolinol
HR20000494A HRP20000494B1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HR20051024A HRP20051024A2 (hr)	1998-01-21	1999-01-20	Farmaceutski aktivni morfolinol

Country Status (30)

Country	Link
US (2)	US6274579B1 (is)
EP (2)	EP1829544A1 (is)
JP (1)	JP2002501025A (is)
KR (1)	KR100568063B1 (is)
CN (2)	CN1255389C (is)
AP (1)	AP1229A (is)
AT (1)	ATE365042T1 (is)
AU (1)	AU755536B2 (is)
BR (1)	BR9907203A (is)
CA (1)	CA2318268A1 (is)
CY (1)	CY1106828T1 (is)
DE (1)	DE69936335T2 (is)
DK (1)	DK1047428T3 (is)
EA (1)	EA002410B1 (is)
EE (1)	EE04452B1 (is)
ES (1)	ES2288012T3 (is)
HR (2)	HRP20051024A2 (is)
HU (1)	HUP0100900A3 (is)
ID (1)	ID26334A (is)
IL (2)	IL161942A0 (is)
IS (1)	IS2494B (is)
NO (2)	NO326878B1 (is)
NZ (3)	NZ520349A (is)
PL (1)	PL193622B1 (is)
PT (1)	PT1047428E (is)
SG (1)	SG115489A1 (is)
SK (1)	SK10912000A3 (is)
TR (1)	TR200002126T2 (is)
WO (1)	WO1999037305A1 (is)
YU (1)	YU67102A (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
WO1999038503A1 (en) *	1998-01-29	1999-08-05	Sepracor Inc.	Pharmacological uses of optically pure (+)-bupropion
US6110973A (en)	1998-01-29	2000-08-29	Sepracor	Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
WO2001026641A2 (en) *	1999-10-13	2001-04-19	Glaxo Group Limited	Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
EP2301537A1 (en) *	2002-05-17	2011-03-30	Duke University	Zonisamide for the treatment of obesity
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
US7384941B2 (en) *	2002-08-23	2008-06-10	Eli Lilly And Company	2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
DK2316456T3 (en)	2003-04-29	2017-09-11	Orexigen Therapeutics Inc	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2005044809A1 (en) *	2003-10-27	2005-05-19	Smithkline Beecham Corporation	Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
EP1734955A2 (en) *	2004-01-13	2006-12-27	Duke University	Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0510593A (pt) *	2004-05-03	2007-11-20	Univ Duke	composições para afetar a perda de peso
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
US7763612B2 (en) *	2006-01-03	2010-07-27	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
AU2007319471B9 (en)	2006-11-09	2012-10-04	Nalpropion Pharmaceuticals Llc	Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
JP5711724B2 (ja)	2009-04-15	2015-05-07	リサーチ・トライアングル・インスティチュート	モノアミン再取り込み阻害剤
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
JP2013526583A (ja)	2010-05-21	2013-06-24	リサーチ・トライアングル・インスティチュート	フェニルモルホリンおよびその類似体
ES2546492T3 (es) *	2010-05-21	2015-09-24	Research Triangle Institute	Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20210012056A (ko)	2012-06-06	2021-02-02	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en)	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
2000
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DK1047428T3 (da)	2007-10-08
NO326878B1 (no)	2009-03-09
DE69936335D1 (de)	2007-08-02
US6274579B1 (en)	2001-08-14
IL161942A0 (en)	2005-11-20
EA200000691A1 (ru)	2001-04-23
PL342012A1 (en)	2001-05-07
EA002410B1 (ru)	2002-04-25
EP1047428A4 (en)	2001-12-19
AP1229A (en)	2003-12-04
IS5568A (is)	2000-07-20
NZ529316A (en)	2004-05-28
EP1829544A1 (en)	2007-09-05
BR9907203A (pt)	2000-10-17
US20020019396A1 (en)	2002-02-14
NO20003721D0 (no)	2000-07-20
HUP0100900A3 (en)	2002-08-28
AU2328099A (en)	1999-08-09
NZ520349A (en)	2004-02-27
NO20003721L (no)	2000-09-19
US6391875B2 (en)	2002-05-21
SG115489A1 (en)	2005-10-28
PT1047428E (pt)	2007-09-07
KR100568063B1 (ko)	2006-04-07
PL193622B1 (pl)	2007-02-28
CN1203858C (zh)	2005-06-01
HRP20051024A2 (hr)	2006-04-30
HUP0100900A2 (hu)	2002-05-29
JP2002501025A (ja)	2002-01-15
HRP20000494A2 (en)	2000-12-31
ATE365042T1 (de)	2007-07-15
KR20010034285A (ko)	2001-04-25
YU67102A (sh)	2004-12-31
CN1255389C (zh)	2006-05-10
EE04452B1 (et)	2005-04-15
WO1999037305A1 (en)	1999-07-29
EE200000438A (et)	2001-12-17
CA2318268A1 (en)	1999-07-29
IS2494B (is)	2009-02-15
CN1528753A (zh)	2004-09-15
IL137346A0 (en)	2001-07-24
AP2000001869A0 (en)	2000-09-30
NZ505809A (en)	2002-09-27
CN1294513A (zh)	2001-05-09
CY1106828T1 (el)	2012-05-23
DE69936335T2 (de)	2008-02-28
EP1047428A1 (en)	2000-11-02
NO20083529L (no)	2000-09-19
AU755536B2 (en)	2002-12-12
TR200002126T2 (tr)	2000-12-21
SK10912000A3 (sk)	2001-04-09
ID26334A (id)	2000-12-14
ES2288012T3 (es)	2007-12-16
EP1047428B1 (en)	2007-06-20

Publication	Publication Date	Title
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
NZ507221A (en)	2003-04-29	Antitumor agent
BR9500758A (pt)	1995-10-24	Formulaçoes farmacêuticas para administraçao oral
DE60039291D1 (de)	2008-08-07	Camptothecinanaloge und deren zubereitungsmethoden
CA2326222A1 (en)	1999-11-04	Medicinal compositions
BR9710372B1 (pt)	2013-02-05	composto, e, composiÇço farmacÊutica.
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
HRP20000181B1 (en)	2006-07-31	2-methyl-thieno-benzodiazepine formulation
NO20015477L (no)	2002-01-11	4,5,6,7-tetrahydroindazolderivater som antitumormidler
RU95101048A (ru)	1996-10-27	Производные пролинамида, фармкомпозиция на их основе
DK1121127T3 (da)	2005-05-02	Orale farmaceutiske sammensætninger, som indeholder buprenorphin
DE69915487D1 (de)	2004-04-15	Erythromycin-derivate mit antibiotischer wirkung
DZ1576A1 (fr)	2002-02-17	Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
EP0816366A4 (en)	1998-07-08	IMIDAZOTHIAZOLE COMPOUNDS
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
DK1073447T3 (da)	2007-09-03	N1-modificerede glycopeptider
ES2192789T3 (es)	2003-10-16	Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
FR2668697B1 (fr)	1997-06-06	Dissecteur, notamment pour chirurgie endoscopique.
EA199900547A1 (ru)	2000-06-26	Состав для полоскания полости рта
SE9701438D0 (sv)	1997-04-17	A new process
ATE491709T1 (de)	2011-01-15	Pyrrolidinohydrochinazoline
MA26677A1 (fr)	2004-12-20	Medicaments antiparkinsoniens.
DK1086695T3 (da)	2005-04-25	Antivirale præparater omfattende yohimbin som aktivt princip
SE9602262D0 (sv)	1996-06-06	New use of derivatives of cystine
RU96115480A (ru)	1998-10-27	Лекарственное средство, обладающее холелитолитическим действием

Legal Events

Date	Code	Title	Description
2000-12-31	A1OB	Publication of a patent application
2001-06-21	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2009-02-28	B1PR	Patent granted
2012-01-18	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20120118 Year of fee payment: 14
2013-07-21	PBON	Lapse due to non-payment of renewal fee	Effective date: 20130121